An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)

drug protocol number
1305-0031
drug sponsor
Boehringer Ingelheim
drug study
BI 1015550
drug trial site
King Abdulaziz Medical City NG (Riyadh)
drug status
Ongoing
drug phase